Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sellas Life Sciences Group Inc (SLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: SLS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.83
1 Year Target Price $5.83
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.17% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 216.52M USD | Price to earnings Ratio - | 1Y Target Price 5.83 |
Price to earnings Ratio - | 1Y Target Price 5.83 | ||
Volume (30-day avg) 3 | Beta 2.27 | 52 Weeks Range 0.77 - 2.27 | Updated Date 07/4/2025 |
52 Weeks Range 0.77 - 2.27 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.36 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -58.79% | Return on Equity (TTM) -144.9% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 188990146 | Price to Sales(TTM) 26.9 |
Enterprise Value 188990146 | Price to Sales(TTM) 26.9 | ||
Enterprise Value to Revenue 20.84 | Enterprise Value to EBITDA -1.71 | Shares Outstanding 99777504 | Shares Floating 91877106 |
Shares Outstanding 99777504 | Shares Floating 91877106 | ||
Percent Insiders 0.34 | Percent Institutions 14.34 |
Upturn AI SWOT
Sellas Life Sciences Group Inc
Company Overview
History and Background
Sellas Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on novel cancer immunotherapies for various cancer types. Founded to develop and commercialize innovative treatments targeting cancer, Sellas is focused on unmet medical needs.
Core Business Areas
- Oncology Immunotherapy: Develops novel immunotherapies targeting cancer. Their primary focus is galinpepimut-S (GPS), a cancer immunotherapeutic targeting the Wilms' tumor protein 1 (WT1) antigen.
Leadership and Structure
Angelos Stergiou, MD, ScD hc is the CEO of Sellas Life Sciences Group. The company has a board of directors overseeing operations and strategy.
Top Products and Market Share
Key Offerings
- Galinpepimut-S (GPS): GPS is a cancer immunotherapeutic targeting the Wilms' tumor protein 1 (WT1) antigen, which is overexpressed in a variety of hematologic malignancies and solid tumors. GPS is currently in late-stage clinical development for acute myeloid leukemia (AML) and multiple myeloma (MM). No significant market share yet as it is in clinical trials. Competitors include companies developing other immunotherapies for AML and MM, such as those focused on CAR-T cell therapy, checkpoint inhibitors, and bispecific antibodies.
Market Dynamics
Industry Overview
The oncology immunotherapy market is rapidly growing, driven by advances in understanding the immune system's role in fighting cancer. There is high demand for effective and personalized treatments.
Positioning
Sellas focuses on WT1-targeted immunotherapy. This allows for a more targeted approach compared to broader immunotherapies. The success of its lead product, GPS, will determine its position.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is very large and growing. Estimated to be over $100 billion by 2025. Sellas is positioned to capture a portion of this market if GPS receives regulatory approval and demonstrates clinical efficacy. The value of the market that Sellas can capture depends on the specific indications and the competition. It is difficult to forecast without knowing if it is going to be approved
Upturn SWOT Analysis
Strengths
- Targeted immunotherapy approach (WT1)
- Late-stage clinical development (GPS)
- Experienced leadership team
Weaknesses
- Single product focus (GPS)
- Reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Potential for regulatory approval of GPS
- Expansion into additional cancer indications
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from other immunotherapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- JNJ
Competitive Landscape
Sellas faces intense competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its targeted immunotherapy approach and focus on WT1. Sellas is an emerging company and is not yet on the level of its competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company being in the clinical development stage.
Future Projections: Future growth depends heavily on the success of GPS clinical trials and potential regulatory approval. Analyst estimates vary based on projected market penetration and pricing.
Recent Initiatives: Focus on advancing GPS through clinical trials, securing funding for development, and exploring potential partnerships.
Summary
Sellas Life Sciences Group Inc. is a clinical-stage biopharmaceutical company with a focus on cancer immunotherapy. The company's success hinges on the clinical development and regulatory approval of its lead product, GPS. The company faces competition from larger pharmaceutical companies. Securing additional funding and partnerships will be crucial for the company's future success. Clinical data is crucial for its success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made after conducting thorough research and consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sellas Life Sciences Group Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2017-12-29 | Founder, President, CEO & Director Dr. Angelos M. Stergiou M.D., ScD h.c. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | |
Full time employees 15 | |||
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.